Aarti Pharmalabs Q3 FY26 Investor Presentation: Revenue ₹4,253 Cr, EBITDA ₹1,030 Cr
Aarti Pharmalabs Limited's Q3 FY26 investor presentation shows standalone revenue of ₹4,253 crore and EBITDA of ₹1,030 crore. Year-to-date revenue is ₹12,179 crore. The company is expanding Xanthine capacity to 9,000+ MTPA and targeting 20-25% global market share. Greenfield capex at Atali is expected to ramp up by Q4 FY26, and brownfield expansion at Tarapur is slated for Q4 FY26.
The announcement provides detailed financial results and strategic updates on capacity expansion. The year-on-year decline in revenue and profit, coupled with sequential growth in EBITDA and future expansion plans, suggests a moderate impact on investor sentiment.
The results show a mixed performance with sequential growth in EBITDA but a year-on-year decline in revenue and profit. While expansion plans are positive, the year-on-year decrease in revenue and profit tempers the overall sentiment.
Aarti Pharmalabs Limited has released its investor presentation for the third quarter of fiscal year 2026, providing a comprehensive overview of its business performance and strategic initiatives.
The company reported standalone operational revenue of ₹4,253 crore for Q3 FY26, a slight increase of 1.9% from ₹4,173 crore in Q2 FY26, but a decrease of 9.7% from ₹4,709 crore in Q3 FY25. EBITDA for the quarter stood at ₹1,030 crore, a significant 39.0% increase from ₹741 crore in the previous quarter and a 10.4% decrease from ₹1,150 crore in the same quarter last year. The EBITDA margin was reported at 24.22% for Q3 FY26.
Year-to-date standalone revenue for the first nine months of FY26 (9M-FY26) was ₹12,179 crore, a 1.9% decrease compared to ₹12,417 crore in 9M-FY25. Consequently, the year-to-date EBITDA was ₹2,720 crore, a 4.0% decrease from ₹2,833 crore in the prior year period.
Consolidated operational revenue for Q3 FY26 was ₹4,323 crore, up 3.3% sequentially but down 19.6% year-on-year. Consolidated EBITDA was ₹1,023 crore, a 36.9% sequential increase and a 20.5% year-on-year decrease. For the nine months ended FY26, consolidated revenue stood at ₹12,368 crore, a 20.3% decrease from ₹15,513 crore in 9M-FY25, with consolidated EBITDA at ₹2,723 crore, down 14.6% year-on-year.
The presentation highlights key business segments including Xanthine Derivatives, API & Intermediates, and CDMO & CMO services. The company is focused on expanding its Xanthine capacity to 9,000+ MTPA, targeting a global market share increase from 15-20% to 20-25%. The Atali greenfield project, with a capacity of 450+ kL, is expected to ramp up by Q4 FY26, focusing on intermediates and CDMO/CMO business. The company also plans brownfield expansion at Tarapur for Xanthine derivatives, with commissioning expected in Q4 FY26.
Future outlook includes a projected increase in reactor capacity to 1,500+ kL and a CDMO revenue growth of 30-40% in FY26E. The company is also investing in renewable power projects to meet half of its power requirements.
What to do with a filing like this
Aarti Pharmalabs Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarti Pharmalabs Limited. Read the original for the full detail.